Xerostomia (dry mouth) is a common manifestation, with an incidence of 0.3% in patients receiving anti-PD-1/PD-L1 monotherapy and 2.5% in those on combination therapy with anti-CTLA-4 agents (ZhangT et al., 2022). The gene discussed is CTLA4; the disease is xerostomia.